## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **LISTING OF CLAIMS:**

- 1. (Currently Amended) A pharmaceutical composition comprising, separately or together, an efficacious amount of (i) loteprednol or <u>loteprednol</u> etabonate a pharmaceutically effective ester thereof and (ii) at least one β<sub>2</sub> adrenoreceptor agonist <u>selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts for simultaneous, sequential or separate administration by inhalation in the treatment of airway disorders in mammals.</u>
- 2. (Currently Amended) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) formoterol wherein the pharmaceutically effective ester of loteprednol is loteprednol etabonate.
- 3. (Currently Amended) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) salmeterol wherein the β₂ adrenoceptor agonist is selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol and their pharmaceutically acceptable salts.

enterdirect amendment 3/17/05